GPRC5D-Targeted CAR T Cells for Myeloma.

ABSTRACT:

Background

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5, member D (GPRC5D) has been identified as an immunotherapeutic target in multiple myeloma. Preclinical studies have shown the efficacy of GPRC5D-targeted CAR T cells, including activity in a BCMA antigen escape model.

Methods

In this phase 1 dose-escalation study, we administered a GPRC5D-targeted CAR T-cell therapy (MCARH109) at four dose levels to patients with heavily pretreated multiple myeloma, including patients with relapse after BCMA CAR T-cell therapy.

Results

A total of 17 patients were enrolled and received MCARH109 therapy. The

SUBMITTER: Mailankody S 

PROVIDER: S-EPMC10309537 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature